title: Drug reaction with eosinophilia and systemic symptoms caused by lenalidomide.
authors.forename: Caterina
authors.initials: C
authors.lastname: Foti
authors.forename: Annarita
authors.initials: A
authors.lastname: Antelmi
authors.forename: Antonio
authors.initials: A
authors.lastname: Mazzocca
authors.forename: Francesco
authors.initials: F
authors.lastname: Saverio Vella
authors.forename: Paolo
authors.initials: P
authors.lastname: Romita
authors.forename: Stefania
authors.initials: S
authors.lastname: Pugliese
authors.forename: Daniela
authors.initials: D
authors.lastname: Lomazzo
authors.forename: Piero
authors.initials: P
authors.lastname: Portincasa
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Palasciano
mesh_terms: D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology*; D004802:Eosinophilia / Q000139:chemically induced* / Q000188:drug therapy; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy*; D011241:Prednisone / Q000627:therapeutic use; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide; D011241:Prednisone